Shigenori Kadowaki

Nagoya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 157 publications

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Journal: JCO precision oncology

Published: July 01, 2026

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: June 18, 2026

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2026

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.

Journal: Future oncology (London, England)

Published: March 24, 2026

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

Journal: British journal of cancer

Published: March 14, 2026

Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

Journal: International journal of clinical oncology

Published: March 12, 2026

Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary.

Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary.

Journal: Future oncology (London, England)

Published: March 02, 2026

Readministration of nivolumab for patients with advanced gastric cancer: a case series.

Readministration of nivolumab for patients with advanced gastric cancer: a case series.

Journal: ESMO gastrointestinal oncology

Published: February 26, 2026

Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study.

Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study.

Journal: Japanese journal of clinical oncology

Published: February 05, 2026

HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.

HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.

Journal: JCO precision oncology

Published: January 21, 2026

Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report.

Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report.

Journal: Therapeutic advances in medical oncology

Published: January 13, 2026

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5-Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single-Institute Propensity Score Analysis.

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5-Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single-Institute Propensity Score Analysis.

Journal: Annals of gastroenterological surgery

Published: January 06, 2026

Showing 1-12 of 157

Last Updated: 09/26/2026